UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION I
631 PARK AVENUE
KING OF PRUSSIA, PENNSYLVANIA 19406

License No. 29-18240-01
Docket No. 030-14715
Control No. 17556

21 SEP 1984

Saddle Brook General Hospital
ATTN: John W. Pollina
Executive Director
300 Market Street
Saddle Brook, New Jersey 07662

Gentlemen:

This is in reference to your application dated May 15, 1984, to renew License Number 29-18240-01. In order to continue our review, we need the following additional information:

1. The cover letter of your application dated May 15, 1984, states you wish to delete Xenon -133 from your License Number 29-18240-01.

   Item 6.A. of NRC Form 313(M) is marked to indicate that you desire Xenon-133 with a maximum possession limit of 30 mci. Please clarify whether you are requesting Xenon-133 to appear on this license.

2. You are currently licensed to possess and use materials listed in Groups I, II, III and IV of Schedule A, Section 35.100 of 10 CFR 35; 10 CFR 31.11 for in vitro studies and Iodine 131 (Iodide) with a possession limit of 200 millicuries.

   Item 6.A. of NRC Form 313(M) indicates you desire Iodine-131 as Iodide for treatment of hyperthyroidism and Iodide-131 as iodide for treatment of thyroid carcinoma. Groups I, II, III, IV, and 10 CFR 31.11 for in vitro studies have not been marked, do you wish to delete these from your license?

3. Item 9. of NRC Form 313(M) lists equipment including G-M meter CDV-700 Serial 218766 Sensitivity 1 mr/hr to - R/hr. Please indicate the highest range of this meter.

4. Effective September 30, 1982, the NRC changed the make up of the radiation safety committee as stated in 10 CFR 35.11(b). We recommend you institute the following regarding the membership of your committee;

Original signed
by Peters

The membership of this committee will consist of at least three members and will include:

1. The radiation safety officer;
2. The hospital administrator, or other administrative official directly responsible to the hospital administrator in the hospital's internal chain of command;
3. A physician specialist from each department where radioactive materials are used; and
4. A representative of the hospital's nursing staff.

The names and qualifications of the committee members will be documented in the committee's records, will be updated as necessary, and will be available for inspection by the NRC.

The above will alleviate the need to amend your license if you replace individual members on the radiation safety committee.

5. Item 10. of NRC Form 313(M) states Equivalent Procedures attached. In reviewing the attached procedures, we were unable to locate the attached procedures pertaining to Item 10. Please submit the equivalent procedures.

6. Item 11. of NRC Form 313(M) states Description and Diagram Attached. The attached diagram does not contain a description of the facility. Please submit the additional information contained in Regulatory Guide 10.8 (Item 11).

On a detailed version of your facility diagram, please indicate the type, dimensions, position and thickness of shielding that you will use for:

A. Storage of radiopharmaceuticals (refrigerated and nonrefrigerated).

B. Storage of radioactive waste, including decay-in-storage prior to disposal as nonradioactive waste. If this areas is located ancillary to your department, describe how you will secure the material. Confirm that this area will be surveyed at least weekly).

C. Identify adjacent areas across the walls from use and storage locations and show that adequate steps have been taken to assure that radiation levels in unrestricted areas do not exceed the limits specified in 10 CFR 20.105 (enclosed).

7. Item 12. and Item 13., of NRC Form 313(M) have not been submitted. Please submit the additional required information.

8. Item 24. of NRC 313(M) does not indicate the use of finger monitoring (ring badge). Please indicate whether this type of monitoring is being used or describe your method for determining the radiation dose to the extremities of personnel handling licensed materials.

9. NRC's June 16, 1980 letter to all medical licensee's requested that an ALARA program be submitted with significant amendment requests filed after August 15, 1980. Please submit a copy of your ALARA Program. You may choose to adopt the model ALARA program in Appendix O of Regulatory Guide 10.8. If you have chosen to adopt the model ALARA program you may simply fill the in the blanks on the first and last pages of the program, have a representative of your management sign the program on the last page, and submit the signed model ALARA program with your response to this letter.

10. You should have available in your department a high-level survey meter capable of reading up to 1 Roentgen per hour in order to measure radiation dose rates that may exist in the vicinity of Tc-99m generators, etc. Please indicate the manufacturer's name, model number, and highest level range of the instrument in your laboratory that will fulfill this need.

We will continue our review upon receipt of this information. Please reply in duplicate to my attention at the Region I office and refer to Mail Control No. 17556.

Sincerely,

Jenny K Johnson for

John E. Glenn, Ph.D., Chief
Nuclear Materials Section B
Division of Engineering and
Technical Programs

Enclosure:
Regulatory Guide 10.8

21 SEP 1984

License No. 29-18240-01
Docket No. 030-14715
Control No. 17556

Saddle Brook General Hospital
ATTN: John W. Pollina
Executive Director
300 Market Street
Saddle Brook, New Jersey 07662

Gentlemen:

This is in reference to your application dated May 15, 1984, to renew License Number 29-18240-01. In order to continue our review, we need the following additional information:

1. The cover letter of your application dated May 15, 1984, states you wish to delete Xenon -133 from your License Number 29-18240-01.

   Item 6.A. of NRC Form 313(M) is marked to indicate that you desire Xenon-133 with a maximum possession limit of 30 mci. Please clarify whether you are requesting Xenon-133 to appear on this license.

2. You are currently licensed to possess and use materials listed in Groups I, II, III and IV of Schedule A, Section 35.100 of 10 CFR 35; 10 CFR 31.11 for in vitro studies and Iodine 131 (Iodide) with a possession limit of 200 millicuries.

   Item 6.A. of NRC Form 313(M) indicates you desire Iodine-131 as Iodide for treatment of hyperthyroidism and Iodide-131 as iodide for treatment of thyroid carcinoma. Groups I, II, III, IV, and 10 CFR 31.11 for in vitro studies have not been marked, do you wish to delete these from your license?

3. Item 9. of NRC Form 313(M) lists equipment including G-M meter CDV-700 Serial 218766 Sensitivity 1 mr/hr to - R/hr. Please indicate the highest range of this meter.

4. Effective September 30, 1982, the NRC changed the make up of the radiation safety committee as stated in 10 CFR 35.11(b). We recommend you institute the following regarding the membership of your committee:

ML10

The membership of this committee will consist of at least three members and will include:

1. The radiation safety officer;
2. The hospital administrator, or other administrative official directly responsible to the hospital administrator in the hospital's internal chain of command;
3. A physician specialist from each department where radioactive materials are used; and
4. A representative of the hospital's nursing staff.

The names and qualifications of the committee members will be documented in the committee's records, will be updated as necessary, and will be available for inspection by the NRC.

The above will alleviate the need to amend your license if you replace individual members on the radiation safety committee.

5. Item 10. of NRC Form 313(M) states Equivalent Procedures attached. In reviewing the attached procedures, we were unable to locate the attached procedures pertaining to Item 10. Please submit the equivalent procedures.

6. Item 11. of NRC Form 313(M) states Description and Diagram Attached. The attached diagram does not contain a description of the facility. Please submit the additional information contained in Regulatory Guide 10.8 (Item 11).

   On a detailed version of your facility diagram, please indicate the type, dimensions, position and thickness of shielding that you will use for:

   A. Storage of radiopharmaceuticals (refrigerated and nonrefrigerated).

   B. Storage of radioactive waste, including decay-in-storage prior to disposal as nonradioactive waste. If this areas is located ancillary to your department, describe how you will secure the material. Confirm that this area will be surveyed at least weekly).

   C. Identify adjacent areas across the walls from use and storage locations and show that adequate steps have been taken to assure that radiation levels in unrestricted areas do not exceed the limits specified in 10 CFR 20.105 (enclosed).

7. Item 12. and Item 13., of NRC Form 313(M) have not been submitted. Please submit the additional required information.

8. Item 24. of NRC 313(M) does not indicate the use of finger monitoring (ring badge). Please indicate whether this type of monitoring is being used or describe your method for determining the radiation dose to the extremities of personnel handling licensed materials.

9. NRC's June 16, 1980 letter to all medical licensee's requested that an ALARA program be submitted with significant amendment requests filed after August 15, 1980. Please submit a copy of your ALARA Program. You may choose to adopt the model ALARA program in Appendix O of Regulatory Guide 10.8. If you have chosen to adopt the model ALARA program you may simply fill the in the blanks on the first and last pages of the program, have a representative of your management sign the program on the last page, and submit the signed model ALARA program with your response to this letter.

10. You should have available in your department a high-level survey meter capable of reading up to 1 Roentgen per hour in order to measure radiation dose rates that may exist in the vicinity of Tc-99m generators, etc. Please indicate the manufacturer's name, model number, and highest level range of the instrument in your laboratory that will fulfill this need.

We will continue our review upon receipt of this information. Please reply in duplicate to my attention at the Region I office and refer to Mail Control No. 17556.

Sincerely,

Original Signed By
Jenny M. Johansen

John E. Glenn, Ph.D., Chief
Nuclear Materials Section B
Division of Engineering and
Technical Programs

Enclosure:
Regulatory Guide 10.8

RI:DETP
Joustra/cop
9/19/84

P
9/21/84

OFFICIAL RECORD COPY 225JOUSTRA8/7/84 - 0003.0.0
09/18/84